Skip to main content

Table 4 Probability of patients with different ER and PR statuses achieving pCR in overall cohort

From: PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China

PR status

ER status

Group H

N (%)

Group HP

N (%)

PR-positive

ER-positive

7 (25.00)

4 (25.00)

ER-negative

1 (33.33)

3 (37.50)

PR-negative

ER-positive

5 (27.78)

4 (80.00)

ER-negative

12 (31.58)

21 (80.77)

Total

 

25 (28.7)

32 (58.2%)